SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Aug 6, 2013
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Aug. 6, 2013 · CIK: 0001533040 · Accession: 0001193125-13-321806
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-188539
Letter
Via EDGAR Transmission and E-Mail Division of Corporate Finance Attn: Jeffrey P. Riedler Re: RXi Pharmaceuticals Corporation Registration Statement on Form S-1 File No. 333-188539
Dear Mr. Riedler:
On behalf of RXi Pharmaceuticals Corporation (the “Company”), we hereby respectfully request that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the Company’s Registration Statement on Form S-1 effective on August 8, 2013 at 9:00 a.m. (Eastern time) or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the Commission. The Company hereby authorizes Ryan Murr or Lisa Kahle of Ropes & Gray LLP, counsel to the Company, to make such telephonic request on our behalf.
In connection with the above-captioned Registration Statement, the Company acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceedings initiated by the Commission or any person under the federal securities laws of the United States.
U.S. Securities and Exchange Commission
Page 2
Please direct any questions regarding this filing to Lisa Kahle at (415) 315-6320.
Sincerely,
/s/ Geert Cauwenbergh
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request RXi PHARMACEUTICALS CORPORATION 1500 WEST PARK DRIVE, SUITE 210 WESTBOROUGH, MA 01581 August 6, 2013 Via EDGAR Transmission and E-Mail U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Mail Stop 6010 Washington, D.C. 20549 Attn: Jeffrey P. Riedler Re: RXi Pharmaceuticals Corporation Registration Statement on Form S-1 File No. 333-188539 Dear Mr. Riedler: On behalf of RXi Pharmaceuticals Corporation (the “Company”), we hereby respectfully request that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the Company’s Registration Statement on Form S-1 effective on August 8, 2013 at 9:00 a.m. (Eastern time) or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the Commission. The Company hereby authorizes Ryan Murr or Lisa Kahle of Ropes & Gray LLP, counsel to the Company, to make such telephonic request on our behalf. In connection with the above-captioned Registration Statement, the Company acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceedings initiated by the Commission or any person under the federal securities laws of the United States. U.S. Securities and Exchange Commission Page 2 Please direct any questions regarding this filing to Lisa Kahle at (415) 315-6320. Sincerely, /s/ Geert Cauwenbergh Geert Cauwenbergh, Dr. Med. Sc. President, Chief Executive Officer and Chief Financial Officer cc: Ryan A. Murr, Ropes & Gray LLP Lisa M. Kahle, Ropes & Gray LLP